Quest Diagnostics has introduced its Thyroglobulin Post-treatment Monitoring Test for monitoring recurrence of thyroid cancer following surgery.

The product is the first clinical test to use mass spectrometry to measure Tg, the company said, and is intended for use in samples where anti-Tg autoantibody production precludes use of conventional immunoassays.


Phenomenex this week released its new Yarra line of aqueous size exclusion chromatography columns for biomolecule analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.